TABLE 2 Primary, secondary and exploratory efficacy endpoints of interest in the intention-to-treat population Endpoint Exenatide QW + IG (n = 231) Placebo + IG (n = 230)(Exenatide QW + IG) − (placebo + IG) Glycaemic control HbA1c, % [mmol/mol]a Baseline, mean /C6SD 8.51 /C60.92 [70 /C610.1] 8.50 /C60.90 [69 /C69.8] Week 28, mean /C6SD 7.55 /C61.20 [59 /C613.1] 8.24 /C61.10 [67 /C612.0] Change, LSM /C6SE (95% CI) −0.96/C60.08 ( −1.11, −0.80) −0.23/C60.08 ( −0.38, −0.07) −0.73 ( −0.93, −0.53); P< .001 [−10.5/C60.9 (−12.1, −8.7)] [ −2.5/C60.9 (−4.2,−0.8)] [ −8.0 (−10.2, −5.8)] Proportion of patients achieving HbA1c <7.0% (<53 mmol/mol)b Number achieving goal (%) [95% CI] 75 (32.5) [26.4, 38.5] 17 (7.4) [4.0, 10.8] 25.1; P< .001 FPG, mmol/L [mg/dL]a Baseline, mean /C6SD 8.22 /C63.12 [148.1 /C656.2] 7.99 /C62.52 [143.8 /C645.4] Week 28, mean /C6SD 7.43 /C62.58 [133.8 /C646.4] 7.87 /C62.67 [141.6 /C648.1]